Equally relevant is Axogen, Inc. (NASDAQ: AXGN), the peripheral-nerve regeneration specialist whose Avance Nerve Graft received FDA Biologics License Application approval in December 2025. On April 28, 2026, the company reported Q1 2026 revenue of $61.5 million, up 26.6% year-over-year from $48.6 million, with gross margin expanding to 75.2% from 71.9%. Management raised full-year 2026 revenue guidance to at least $270 million, implying growth of at least 20%. Analyst sentiment followed. Axogen had its price target raised to $48 from $41 at Raymond James, to $50 from $40 at Lake Street, and to $50 from $42 at Citizens — all in late April 2026 — with shares trading near the upper end of their 52-week range around the $42 level. Cigna added broad coverage for Avance in April, further reinforcing reimbursement momentum.